TGA wants to ban compounded semaglutide because of safety concerns
Compounding the diabetes drug could be off the table under the watchdog's proposals.
The TGA wants to ban pharmacists from compounding their own versions of semaglutide based on safety concerns about the “commercial scale” of operations.
The watchdog has proposed removing all medicines containing GLP-1 receptor agonist analogues (GLP-1 RAs) from the legal provisions that let pharmacists compound medications without a drug manufacturing licence.
This would have the effect of banning the compounding of semaglutide-like medications by pharmacists, in a decision expected to be made by June.
The TGA said it was concerned that semaglutide compounding had moved away from one-off formulations for individual patients with a valid prescription.
